WCLC 2025: New HERNEXEOS® data demonstrated promising intracranial responses in patients with advanced HER2m NSCLC with brain mets
“This data update showcases zongertinib’s strong efficacy and safety profile in patients with HER2-mutant non-small cell lung cancer with and without brain metastases,” said the presenting investigator, Dr. Gerrina Ruiter, MD., PhD., at the Department of Clinical Pharmacology and Thoracic Oncology, Netherlands Cancer Institute, Netherlands. “Patients with brain metastases historically have had a very poor prognosis and few effective treatment options. These data showed zongertinib is active in the brain and underscore its potential for patients who have not received prior radiotherapy.”
Share:
More News
“We are pleased to evaluate the clinical combination of IDE892 with RG6505 in MTAP-deleted RAS-mutant PDAC,” said Yujiro S. Hata, President and Chief Executive Officer, IDEAYA Biosciences. “This collaboration aligns with our broader clinical strategy to evaluate rational combinations with assets in our MTAP-deletion portfolio, and there remains especially high
“In the first reported data from the clinical combinations of our PRMT5 inhibitor vopimetostat and RAS(ON) inhibitors, we saw extremely encouraging early results, with 92% of patients with PDAC in the vopimetostat plus daraxonrasib arm achieving an objective response, supporting the preclinical data showing synergistic activity of PRMT5 + RAS
“Non-small cell lung cancer is the most prevalent lung disease with more than 8,000 patients in the U.S. diagnosed each year with KRAS G12D-mutations. Receiving Fast Track designation for VS-7375 reinforces both the significant unmet need and the potential of VS-7375 to improve outcomes for patients with KRAS G12D-mutated lung
“KRAS has notoriously been considered an undruggable target and patients with KRAS-driven cancers continue to face limited treatment options with survival measured in months, not years,” said John Reed, M.D., Ph.D., Executive Vice President, Innovative Medicine, Research & Development, Johnson & Johnson. “We believe the proprietary Firelink™ platform will overcome